Sarcoma  >>  AiRuiKa (camrelizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AiRuiKa (camrelizumab) / HLB Bio Group
NCT05643417: Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Not yet recruiting
1
80
RoW
HAIC、Bevacizumab、Camrelizumab, Camrelizumab brand name: ai rui ka; Bevacizumab brand name: ai rui tuo
Fudan University
Metastatic Liver Cancer
10/23
10/24
NCT04074564: MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Recruiting
1
60
RoW
MASCT-I, Camrelizumab,Apatinib
HRYZ Biotech Co.
Sarcoma
08/24
12/24

Download Options